The life sciences and healthcare industries have remained a major focus for government enforcers in the Trump administration. Agencies have continued to closely examine medical device and pharmaceuticals markets with a strong focus on innovation effects and potential entry. That analysis is often challenging, as these markets are characterized by regulatory requirements, scarce and highly specialized human capital, complex intellectual property coverage, long and expensive product development cycles, development and manufacturing overlaps among product lines, and narrowly specialized products—not to mention potentially lifesaving impacts for patients.
Read the full article: 2026 Antitrust Year in Preview: Life Sciences and Healthcare //
Source: https://www.wsgr.com/en/insights/2026-antitrust-year-in-preview-life-sciences-and-healthcare.html